RBC Capital analyst Luca Issi maintains $Intellia Therapeutics (NTLA.US)$ with a buy rating, and adjusts the target price from $54 to $47.
According to TipRanks data, the analyst has a success rate of 21.7% and a total average return of -17.9% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Intellia Therapeutics (NTLA.US)$'s main analysts recently are as follows:
Despite ongoing uncertainties related to politics and rates, the overall condition of the Biopharma sector is seen as significantly enhanced compared to its 2022 lows. Furthermore, there's a favorable view towards stocks involved in late-stage clinical trials or those in the early launch phase. Yet, there's growing interest among investors towards Phase 1 clinical programs that present derisking data and near-term catalysts.
The fourth quarter is expected to be generally solid for large and mid-cap commercial stage companies in the Biotech sector, supported by seasonal tailwinds. However, the expectations for 2025 might be overly optimistic, with several product launches already factored into valuations and the sustainability of key franchises posing potential challenges.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
